Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

400 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.
van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AK, Mathijssen RH, Boven E, van der Straaten T, Baak-Pablo RF, Wessels JA, Guchelaar HJ, Gelderblom H. van Erp NP, et al. Among authors: mathijssen rh. J Clin Oncol. 2009 Sep 10;27(26):4406-12. doi: 10.1200/JCO.2008.21.7679. Epub 2009 Aug 10. J Clin Oncol. 2009. PMID: 19667267
Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib.
Steeghs N, Mathijssen RH, Wessels JA, de Graan AJ, van der Straaten T, Mariani M, Laffranchi B, Comis S, de Jonge MJ, Gelderblom H, Guchelaar HJ. Steeghs N, et al. Among authors: mathijssen rh. Invest New Drugs. 2011 Oct;29(5):953-62. doi: 10.1007/s10637-010-9405-7. Epub 2010 Feb 25. Invest New Drugs. 2011. PMID: 20182906 Free PMC article. Clinical Trial.
Pharmacogenetics of tomorrow: the 1 + 1 = 3 principle.
Pander J, Wessels JA, Mathijssen RH, Gelderblom H, Guchelaar HJ. Pander J, et al. Among authors: mathijssen rh. Pharmacogenomics. 2010 Jul;11(7):1011-7. doi: 10.2217/pgs.10.87. Pharmacogenomics. 2010. PMID: 20602619
Myelosuppression by sunitinib is flt-3 genotype dependent.
van Erp NP, Mathijssen RH, van der Veldt AA, Haanen JB, Reyners AK, Eechoute K, Boven E, Wessels JA, Guchelaar HJ, Gelderblom H. van Erp NP, et al. Among authors: mathijssen rh. Br J Cancer. 2010 Aug 24;103(5):757-8. doi: 10.1038/sj.bjc.6605813. Epub 2010 Aug 3. Br J Cancer. 2010. PMID: 20683446 Free PMC article. No abstract available.
Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation.
de Jonge MJ, Slingerland M, Loos WJ, Wiemer EA, Burger H, Mathijssen RH, Kroep JR, den Hollander MA, van der Biessen D, Lam MH, Verweij J, Gelderblom H. de Jonge MJ, et al. Among authors: mathijssen rh. Eur J Cancer. 2010 Nov;46(16):3016-21. doi: 10.1016/j.ejca.2010.07.015. Epub 2010 Aug 26. Eur J Cancer. 2010. PMID: 20801016 Clinical Trial.
Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib.
van der Veldt AA, Eechoute K, Gelderblom H, Gietema J, Guchelaar HJ, van Erp NP, van den Eertwegh AJ, Haanen JB, Mathijssen RH, Wessels JA. van der Veldt AA, et al. Among authors: mathijssen rh. Clin Cancer Res. 2011 Feb 1;17(3):620-9. doi: 10.1158/1078-0432.CCR-10-1828. Epub 2010 Nov 19. Clin Cancer Res. 2011. PMID: 21097692
Drug transporters and imatinib treatment: implications for clinical practice.
Eechoute K, Sparreboom A, Burger H, Franke RM, Schiavon G, Verweij J, Loos WJ, Wiemer EA, Mathijssen RH. Eechoute K, et al. Among authors: mathijssen rh. Clin Cancer Res. 2011 Feb 1;17(3):406-15. doi: 10.1158/1078-0432.CCR-10-2250. Epub 2010 Dec 16. Clin Cancer Res. 2011. PMID: 21163869 Review.
400 results